Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin Empirical Therapy for Invasive Candidiasis in ICU
NCT01045798Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2010
- Primary completion
- Apr 2012
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in invasive candidiasis comparing Caspofungin with Placebo (2 arms). Primary endpoint: Proportion of Patients Discontinued From Study Therapy to be Treated With Empirical Antifungal Therapy. Started Dec 2010; status: terminated.
02
Drugs
caspofungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on NCT01045798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01045798.